Alternative therapies for postmenopausal women

International Journal of Fertility and Women's Medicine

Volumn 50, Issue 3, 2005, Pages 101-114

  Speroff, Leon ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

(Review article 133 references); Black cohosh; DHEA; Equol; Estriol; Isoflavones; Phytoestrogens; Progesterone (transdermal); Red clover; Soy; St. John's wort

Indexed keywords

ANGELICA EXTRACT; ANGELICA SINENSIS EXTRACT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; CHAMOMILE; CIMICIFUGA RACEMOSA EXTRACT; CONJUGATED ESTROGEN; DAIDZEIN; DIGOXIN; EPHEDRA SINICA EXTRACT; EQUOL; ESTRIOL; ESTROGEN; GENISTEIN; GESTAGEN; GINKGO BILOBA EXTRACT; GINSENG EXTRACT; GLYCYRRHIZA EXTRACT; HYPERICUM PERFORATUM EXTRACT; IPRIFLAVONE; ISOFLAVONE; ISOFLAVONE DERIVATIVE; PHYTOESTROGEN; PLACEBO; PRIMROSE OIL; PROGESTERONE; SOYBEAN PROTEIN; THEOPHYLLINE; UNINDEXED DRUG; VALERIAN; PLANT EXTRACT;

ALZHEIMER DISEASE; ANTICOAGULATION; BLOOD CLOTTING DISORDER; BRADYCARDIA; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DEPRESSION; DRUG BLOOD LEVEL; DRUG HYPERSENSITIVITY; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HOT FLUSH; HUMAN; HYPERICUM PERFORATUM; HYPERTENSION; INSOMNIA; MASTALGIA; MENOPAUSAL SYNDROME; META ANALYSIS; NAUSEA; OSTEOPOROSIS; PHOTOSENSITIVITY; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; PRESCRIPTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SODIUM RETENTION; SYSTEMATIC REVIEW; TREATMENT PLANNING; VOMITING; ALTERNATIVE MEDICINE; DIET SUPPLEMENTATION; EVIDENCE BASED MEDICINE; FEMALE; LIFESTYLE; MIDDLE AGED; PHYTOTHERAPY; POSTMENOPAUSE OSTEOPOROSIS; STANDARD; UNITED STATES; WOMEN'S HEALTH;

COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; EVIDENCE-BASED MEDICINE; FEMALE; HOT FLASHES; HUMANS; LIFE STYLE; META-ANALYSIS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PHYTOTHERAPY; PLANT EXTRACTS; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; WOMEN'S HEALTH;

EID: 33644815172     PISSN: 1534892X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (133)

1. Astin JA: Why patients use alternative medicine: results of a national study. JAMA 279:1548-1553, 1998.
2. Eisenberg DM, Davis RB, Ettner SL, et al: Trends in alternative medicine use in the United States, 1990-1997: results of a follow-up national survey. JAMA 280:1569-1575, 1998.
3. Murkies AL, Wilcox G, Davis SR: Phytoestrogens. J Clin Endocrinol Metab 83:297-303, 1998.
4. Tham DM, Gardner CD, Haskell WL: Potential health benefits of dietary phytoestrogens: a review of the clinical, epidemiological, and mechanistic evidence. J Clin Endocrinol Metab 83:2223-2235, 1998.
5. Kuiper GGJM, Carlsson B, Grandien K, et al: Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors a and b. Endocrinology 138:863-870, 1997.
6. Anderson RL, Wolf WJ: Compositional changes in trypsin inhibitors, phytic acid, saponins and isoflavones related to soybean processing. J Nutr 125(Suppl):581S-588S, 1995.
7. Messina M: Isoflavone intakes by Japanese were overestimated (letter to the editor). Am J Clin Nutr 62:645, 1995.
8. Coward L, Barnes NC, Setchell KDR, et al: The isoflavones genistein and daidzein soybean foods from American and Asian diets. J Agric Food Chem 41:1961-1967, 1993.
9. Cassidy A, Bingham S, Setchell KDR: Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr 60:333-340, 1994.
10. Ashraf HR, White M, Klubek B: Microbiological survey of tofu sold in a rural Illinois county. J Food Prot 62:1050-1053, 1999.
11. MacLennan AH, Henry D, Hills S, et al: Oral oestrogen replacement therapy versus placebo for hot flushes, in Farquhar C, Cooke I, Barlow D (eds): Menstrual Disorders Module of the Cochrane Database of Systematic Reviews. Oxford: Cochrane Library Update Software, 2000.
12. Albertazzi P, Pansini F, Bonaccorsi G, et al: The effect of dietary soy supplementation on hot flushes. Obstet Gynecol 91:6-11, 1998.
13. Scambia G, Mango D, Signorile PG, et al: Clinical effects of a standardized soy extract in postmenopausal women: a pilot study. Menopause 7:105-111, 2000.
14. Upmalis DH, Lobo R, Bradley L, et al: Vasomotor symptom relief by soy isoflavone extract tablets in postmenopausal women: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 7:236-242, 2000.
15. Faure ED, Chantre P, Mares P: Effects of a standardized soy extract on hot flushes: a multicenter, double-blind, randomized, placebo-controlled study. Menopause 9:329-334, 2002.
16. Quella SK, Loprinzi CL, Barton DL, et al: Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: a North Central Cancer Treatment Group trial. J Clin Oncol 18:1068-1074, 2000.
17. Kotsopoulos D, Dalais FS, Liang Y-L, et al: The effects of soy protein containing phytoestrogens on menopausal symptoms in postmenopausal women. Climacteric 3:161-167, 2000.
18. St. Germain A, Peterson CT, Robinson JG, et al: Isoflavone-rich or isoflavone-poor soy protein does not reduce menopausal symptoms during 24 weeks of treatment. Menopause 8:17-26, 2001.
19. Van Patten CL, Olivotto IA, Chambers GK, et al: Effect of soy phytoestrogens on hot flashes in postmenopausal women with breast cancer: a randomized, controlled clinical trial. J Clin Oncol 20:1449-1455, 2002.
20. Baber RJ, Templeman C, Morton T, et al: Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 2:85-92, 1999.
21. Knight DC, Howes JB, Eden JA: The effect of Promensil™, an isoflavone extract, on menopausal symptoms. Climacteric 2:79-84, 1999.
22. van de Wijer PHM, Barentsen R: Isoflavones from red clover (Promensil®) significantly reduce menopausal hot flush symptoms compared with placebo. Maturitas 42:187-193, 2002.
23. Hirata JD, Swiersz LM, Zell B, et al: Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 68:981-986, 1997.
24. Wiklund IK, Mattsson LA, Lindgren R, et al: Effects of a standardized ginseng extract on quality of life and physiological parameters in symptomatic postmenopausal women: a double-blind, placebo-controlled trial. Swedish Alternative Medicine Group. Int J Clin Pharmacol Res 19:89-99, 1999.
25. Barton DL, Loprinzi CL, Quella SK, et al: Prospective evaluation of vitamin E for hot flashes in breast cancer survivors. J Clin Oncol 16:495-500, 1998.
26. Khoo SK, Munro C, Battistutta D: Evening primrose oil and treatment of premenstrual syndrome. Med J Aust 153:189, 1990.
27. Collins A, Cerin A, Coleman G, et al: Essential fatty acids in the treatment of premenstrual syndrome. Obstet Gynecol 81:93-98, 1993.
28. Chenoy R, Hussain S, Tayob Y, et al: Effect of oral gamolenic acid from evening primrose oil on menopausal flushing. Br Med J 308:501-503, 1994.
29. Lieberman S: A review of the effectiveness of Cimicifuga racemosa (Black Cohosh) for the symptoms of menopause. J Womens Health 7:525-529, 1998.
30. Brucker A: Essay on the phytotherapy of hormonal disorders in women. Med Welt 44:223, 1960.
31. Stoll W: Phytotherapy influences atrophic vaginal epithelium. Therapeutikon 1:23, 1987.
32. Duker EM, Kopanski HJ, Wuttke W: Effects of extracts from Cimicifuga racemosa on gonadotropin release in menopausal women and ovariectomized rats. Planta Med 57:420, 1991.
33. Jacobson JS, Troxel AB, Evans J, et al: Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 19:2739-2745, 2001.
34. Plouffe LJ, Trott EA, Sanal S, et al: Sertraline (Zoloft) for the management of hot flashes in women on tamoxifen: a randomized controlled pilot trial (abstract). Menopause 4:262, 1997.
35. Loprinzi CL, Pisansky TM, Fonseca R, et al: Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 16:2377-2381, 1998.
36. Stearns V, Isaacs C, Rowland J, et al: A pilot trial assessing the efficacy of paroxetine hydrochloride (Paxil®) in controlling hot flashes in breast cancer survivors. Ann Oncol 11:17-22, 2000.
37. Loprinzi CL, Sloan JA, Perez EA, et al: Phase III evaluation of fluoxetine for treatment of hot flashes. J Clin Oncol 20:1578-1583, 2002.
38. Anderson JW, Johnstone B, Cook-Newell ME: Meta-analysis of the effects of soy protein intake on serum lipids. N Engl J Med 333:276-282, 1995.
39. Clarkson TB, Anthony M, Morgan TM: Inhibition of postmenopausal atherosclerosis progression: a comparison of the effects of conjugated equine estrogens and soy phytoestrogens. J Clin Endocrinol Metab 86:41-47, 2001.
40. Greaves KA, Parks JS, Williams JK, et al: Intact dietary soy protein, but not adding an isoflavone-rich soy extract to casein, improves plasma lipids in ovariectomized cynomolgus monkeys. J Nutr 129:1585-1592, 1999.
41. Greaves KA, Wilson MD, Rudel L, et al: Consumption of soy protein reduces cholesterol absorption compared to casein protein alone or supplemented with an isoflavone extract or conjugated equine estrogen in ovariectomized cynomolgus monkeys. J Nutr 130:820-826, 2000.
42. Anthony MS, Clarkson TB, Williams JK: Effects of soy isoflavones on atherosclerosis: potential mechanisms. Am J Clin Nutr 68:1390S-1393S, 1998.
43. Anthony MS, Clarkson TB, Hughes CL, Jr, et al: Soybean isoflavones improve cardiovascular risk factors without affecting the reproductive system of peripubertal Rhesus monkeys. J Nutr 126:43-50, 1996.
44. Anthony MS, Clarkson TB: Comparison of soy phytoestrogens and conjugated equine estrogens on atherosclerosis progression in postmenopausal monkeys (abstract). Circulation 90:829, 1998.
45. Honoré EK, Williams JK, Anthony MS, et al: Soy isoflavones enhance coronary vascular reactivity in atherosclerotic female macaques. Fertil Steril 67:148-154, 1997.
46. Williams JK, Anthony MS, Clarkson TB: Interactive effects of soy protein and estradiol on coronary artery reactivity in atherosclerotic, ovariectomized monkeys. Menopause 8:307-313, 2001.
47. Clarkson TB, Anthony MS: Effect of hormone replacement therapy on internal carotid artery atherosclerosis of postmenopausal monkeys (abstract). Circulation 97:830, 1998.
48. Crouse JR 3rd, Morgan T, Terry JG, et al: A randomized trial comparing the effect of casein with that of soy protein containing varying amounts of isoflavones on plasma concentrations of lipids and lipoproteins. Arch Intern Med 159:2070-2076, 1999.
49. Potter SM, Baum JA, Teng H, et al: Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. Am J Clin Nutr 68(Suppl):1375S-1379S, 1998.
50. Washburn S, Burke GL, Morgan T, et al: Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause 6:7-13, 1999.
51. Merz-Demlow BE, Duncan AM, Wangen KE, et al: Soy isoflavones improve plasma lipids in normocholesterolemic, premenopausal women. Am J Clin Nutr 71:1462-1469, 2000.
52. Teixeira SR, Potter SM, Weigel R, et al: Effects of feeding 4 levels of soy protein for 3 and 6 wk on blood lipids and apolipoproteins in moderately hypercholesterolemic men. Am J Clin Nutr 71:1077-1084, 2000.
53. Simons LA, von Konigsmark M, Simons J, et al: Phytoestrogens do not influence lipoprotein levels or endothelial function in healthy, postmenopausal women. Am J Cardiol 11:1297-1301, 2000.
54. Jayagopal V, Albertazzi P, Kilpatrick ES, et al: Beneficial effects of soy phytoestrogen intake in postmenopausal women with type 2 diabetes. Diabetes Care 25:1709-1714, 2002.
55. Nestel PJ, Pomeroy S, Kay S, et al: Isoflavones from red clover improve systemic arterial compliance but not plasma lipids in menopausal women. J Clin Endocrinol Metab 84:895-898, 1999.
56. Food and Drug Administration: Food labelling: health claims; soy protein and coronary heart disease. Federal Register 64:57699-57733, 1999.
57. Hodgson JM, Puddey IB, Beilin LJ, et al: Supplementation with isoflavonoid phytoestrogens does not alter serum lipid concentrations: a randomized controlled trial in humans. J Nutr 128:728-732, 1998.
58. Dewell A, Hollenbeck CB, Bruce B: The effects of soy-derived phytoestrogens on serum lipids and lipoproteins in moderately hypercholesterolemic postmenopausal women. J Clin Endocrinol Metab 87:118-121, 2002.
59. Arjmandi BH, Birnbaum R, Goyal NV, et al: Bone-sparing effect of soy protein in ovarian hormone-deficient rats is related to its isoflavone content. Am J Clin Nutr 68(Suppl):1364S-1368S, 1998.
60. Jayo MJ, Anthony MS, Register TC, et al: Dietary soy isoflavones and bone loss: a study in ovariectomized monkeys (abstract). J Bone Miner Res 11(Suppl 1):S228, 1996.
61. Lees CJ, Ginn TA: Soy protein isolate diet does not prevent increased cortical bone turnover in ovariectomized macaques. Calcif Tissue Int 62:557-558, 1998.
62. Alekel DL, Peterson C, St. Germain A, et al: Isoflavone-rich soy isolate exerts significant bone-sparing in the lumbar spine of perimenopausal women (abstract). Annual Meeting, American Society of Bone Mineral Research, 1999.
63. Gallagher JC, Rafferty K, Wilson MD, et al: The effect of soy protein on bone metabolism (abstract). North American Menopause Society Annual Meeting, 1999.
64. Lucas EA, Wild RD, Hammond LJ, et al: Flaxseed improves lipid profile without altering biomarkers of bone metabolism in postmenopausal women. J Clin Endocrinol Metab 87:1527-1532, 2002.
65. Nakamura T, Turner CH, Yoshikawa T, et al: Do variations in hip geometry explain differences in hip fracture risk between Japanese and white Americans? J Bone Miner Res 9:1071-1076, 1994.
66. Melis GB, Paoletti AM, Cagnacci A: Ipriflavone prevents bone loss in postmenopausal women. Menopause 3:27-31, 1996.
67. Gennari C, Agnusdei D, Crepaldi G, et al: Effect of ipriflavone-a synthetic derivative of natural isoflavones-on bone mass loss in the early years after menopause. Menopause 5:9-15, 1998.
68. de Aloysio D, Gambacciani M, Altieri P, et al: Bone density changes in postmenopausal women with the administration of ipriflavone alone or in association with low-dose ERT. Gynecol Endocrinol 11:289-293, 1997.
69. Gambacciani M, Ciaponi M, Cappagli B, et al: Effects of combined low dose of the isoflavone derivative ipriflavone and estrogen replacement on bone mineral density and metabolism in postmenopausal women. Maturitas 28:75-81, 1997.
70. Alexandersen P, Toussaint A, Christiansen C, et al: Ipriflavone in the treatment of postmenopausal osteoporosis. A randomized controlled trial. JAMA 285:1482-1488, 2001.
71. Pan Y, Anthony M, Clarkson TB: Effect of estradiol and soy phytoestrogens on choline acetyltransferase and nerve growth factor mRNAs in the frontal cortex and hippocampus of female rats. Proc Soc Exp Biol Med 221:118-125, 1999.
72. Pan Y, Anthony M, Watson S, et al: Soy phytoestrogens improve radial arm maze performance in ovariectomized retired breeder rats and do not attenuate benefits of 17β-estradiol treatment. Menopause 7:230-235, 2000.
73. White LR, Petrovitch H, Ross GW, et al: Brain aging and midlife tofu consumption. J Am Coll Nutr 19:242-255, 2000.
74. Adlercreutz H, Mazur W: Phyto-oestrogens and western diseases. Ann Med 29:95-120, 1997.
75. Goodman MT, Wilkens LR, Hankin JH, et al: Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146:294-306, 1997.
76. Ingram D, Sanders K, Kolybaba M, et al: Case-control study of phyto-oestrogens and breast cancer. Lancet 350:990-994, 1997.
77. Murkies A, Dalais FS, Briganti EM, et al: Phytoestrogens and breast cancer in postmenopausal women: a case control study. Menopause 7:289-296, 2000.
78. Lee HP, Gourley L, Duffy SW, et al: Dietary effect on breast cancer risk in Singapore. Lancet 337:1197-1200, 1991.
79. Wu AH, Ziegler RG, Horn-Ross PL, et al: Tofu and risk of breast cancer in Asian-Americans. Cancer Epidemiol Biomarkers Prev 5:901-906, 1996.
80. Zheng W, Dai Q, Custer LJ, et al: Urinary excretion of isoflavonoids and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 8:35-40, 1999.
81. Messina MJ, Persky V, Setchell KDR, et al: Soy intake and cancer risk: a review of the in vitro and in vivo data. Nutr Cancer 21:113-131, 1994.
82. Petrakis NL, Barnes S, King EB, et al: Stimulatory influence of soy protein isolate on breast secretion in pre- and postmenopausal women. Cancer Epidemiol Biomarkers Prev 5:785-794, 1996.
83. Lamartiniere CA: Protection against breast cancer with genistein: a component of soy. Am J Clin Nutr 71(Suppl):1705S-1707S, 2000.
84. Cohen LA, Zhao Z, Pittman B, et al: Effect of intact and isoflavone-depleted soy protein on NMU-induced rat mammary tumorigenesis. Carcinogenesis 21:929-935, 2000.
85. Foth D, Cline JM: Effects of mammalian and plant estrogens on mammary glands and uteri of macaques. Am J Clin Nutr 68(Suppl):1413S-1417S, 1998.
86. Foth D, Cline JM, Romer T: Effect of isoflavones on mammary gland and endometrium of postmenopausal macaques (Macaca fasicularis). Zentralbl Gynäkol 122:96-102, 2000.
87. Lu L-JW, Anderson KE, Grady JJ, et al: Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev 5:63-70, 1996.
88. Wu AH, Stancyzk FZ, Hendrich S, et al: Effects of soy foods on ovarian function in premenopausal women. Br J Cancer 82:1879-1886, 2000.
89. Lu LW, Anderson KE, Grady JJ, et al: Effects of an isoflavone-free soy diet on ovarian hormones in premenopausal women. J Clin Endocrinol Metab 86:3045-3052, 2001.
90. Martini MC, Dancisak BB, Haggans CJ, et al: Effects of soy intake on sex hormone metabolism in premenopausal women. Nutr Cancer 34:133-139, 1999.
91. Baird DD, Umbach DM, Lansdell L, et al: Dietary intervention study to assess estrogenicity of dietary soy among postmenopausal women. J Clin Endocrinol Metab 80:1685-1690, 1995.
92. Duncan AM, Underhill KE, Xu X, et al: Modest hormonal effects of soy isoflavones in postmenopausal women. J Clin Endocrinol Metab 84:3479-3484, 1999.
93. Lu LJ, Cree M, Josyula S, et al: Increased urinary excretion of 2-hydroxyestrone but not 16-alpha-hydroxyestrone in premenopausal women during a soya diet containing isoflavones. Cancer Res 60:1299-1305, 2000.
94. Hargreaves DF, Potten CS, Harding C, et al: Two-week dietary soy supplementation has an estrogenic effect on normal premenopausal breast. J Clin Endocrinol Metab 84:4017-4024, 1999.
95. McMichael-Phillips DF, Harding C, Morton M, et al: Effects of soy-protein supplementation on epithelial proliferation in the histologically normal breast. Am J Clin Nutr 68(Suppl):1431S-1435S, 1998.
96. Balk JL, Whiteside DA, Naus G, et al: A pilot study of the effects of phytoestrogen supplementation on postmenopausal endometrium. J Soc Gynecol Investig 9:238-242, 2002.
97. Setchell KDR, Brown NM, Lydeking-Olsen E: The clinical importance of the metabolite equol-a clue to the effectiveness of soy and its isoflavones. J Nutr 132:3577-3584, 2002.
98. Lydeking-Olsen E, Jensen J-BE, Setchell KDR, et al: Isoflavone-rich soy milk prevents bone-loss in the lumbar spine of postmenopausal women. A 2-year study. J Nutr 132:581S (abstract), 2002.
99. Oken BS, Storzbach DM, Kaye JA: The efficacy of ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55:1409-1415, 1998.
100. van Dongen MC, van Rossum E, Kessels AG, et al: The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J Am Geriatr Soc 48:1183-1194, 2000.
101. Solomon PR, Adams F, Silver A, et al: Ginkgo for memory enhancement. A randomized controlled trial. JAMA 288:835-840, 2002.
102. Gaster B, Holroyd J: St. John's wort for depression: a systematic review. Arch Intern Med 160:152-156, 2000.
103. Kim HL, Streitzer J, Goebert D: St. John's wort for depression: a meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187:532-538, 1999.
104. Linde K, Mulrow CD: St John's wort for depression. Cochrane Database Syst Rev CD000448, 2000.
105. Shelton RC, Keller MB, Glelenberg A, et al: Effectiveness of St John's Wort in major depression. A randomized controlled trial. JAMA 285:1978-1986, 2001.
106. Hypericum Depression Trial Study Group: Effect of Hypericum perforatum (St John's Wort) in major depressive disorder. A randomized controlled trial. JAMA 287:1807-1814, 2002.
107. Food and Drug Administration: Risk of drug interactions with St. John's wort and indinavir and other drugs. FDA Public Health Advisory, February 10, 2000.
108. Moore L, Goodwin B, Jones SA, et al: St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci USA 97:7500-7502, 2000.
109. Lemon HM: Estriol prevention of mammary carcinoma induced by 7,12-dimethylbenz(a)anthracene. Cancer Res 35:1341-1353, 1975.
110. Takahashi K, Okada M, Ozaki T, et al: Safety and efficacy of oestriol for symptoms of natural or surgically induced menopause. Hum Reprod 15:1028-1036, 2000.
111. Grodstein F, Stampfer MJ, Falkeborn M, et al: Postmenopausal hormone therapy and risk of cardiovascular disease and hip fracture in a cohort of Swedish women. Epidemiology 10:476-480, 1999.
112. Weiderpass E, Baron JA, Adami HO, et al: Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 353:1824-1828, 1999.
113. Lindsay R, Hart DM, MacLean A, et al: Bone loss during oestriol therapy in postmenopausal women. Maturitas 1:279-285, 1979.
114. Devogelaer JP, Lecart C, Dupret P, et al: Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. Maturitas 28:243-249, 1998.
115. Katzenellenbogen BS: Biology and receptor interactions of estriol and estriol derivatives in vitro and in vivo. J Steroid Biochem 20:1033, 1984.
116. Melamed M, Castraño E, Notides AC, et al: Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. Mol Endocrinol 11:1868-1878, 1997.
117. Lee JR: Osteoporosis reversal: the role of progesterone. Clin Nutr Rev 10:384-389, 1990.
118. Cooper A, Spencer C, Whitehead MI, et al: Systemic absorption of progesterone from Progest cream in postmenopausal women. Lancet 351:1255-1256, 1998.
119. Carey BJ, Carey AH, Patel S, et al: A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women. Br J Obstet Gynaecol 107:722-726, 2000.
120. Burry KA, Patton PE, Hermsmeyer K: Percutaneous absorption of progesterone in postmenopausal women treated with transdermal estrogen. Am J Obstet Gynecol 180:1504-1511, 1999.
121. Leonnetti HB, Longo S, Anasti JN: Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. Obstet Gynecol 94:225-228, 1999.
122. Wren BG, McFarland K, Edwards L, et al: Effect of sequential transdermal progesterone cream on endometrium, bleeding pattern, and plasma progesterone and salivary progesterone levels in postmenopausal women. Climacteric 3:155-160, 2000.
123. Wren BG, Champion SM, Willetts K, et al: Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women. Menopause 10:13-18, 2003.
124. O'Leary P, Feddema P, Chan K, et al: Salivary, but not serum or urinary levels of progesterone are elevated after topical application of progesterone cream to pre- and postmenopausal women. Clin Endocrinol 53:615-620, 2000.
125. Lewis JG, McGill H, Patton V, et al: Caution on the use of saliva measurements to monitor absorption of progesterone from transdermal creams in postmenopausal women. Maturitas 41:1-6, 2002.
126. Komesaroff PA, Black C, Cable V, et al: Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. Climacteric 4:144-150, 2001.
127. Slayden SM, Crabbe L, Bae S, et al: The effect of 17b-estradiol on adrenocortical sensitivity, responsiveness, and steroidogenesis in postmenopausal women. J Clin Endocrinol Metab 83:519-524, 1998.
128. Baulieu EE, Thomas G, Legrain S, et al: Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 97:4279-4284, 2000.
129. Barnhart KT, Freeman E, Grisso JA, et al: The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 84:3896-38902, 1999.
130. Johannes CB, Stellato RK, Feldman HA, et al: Relation of dehydroepiandrosterone and dehydroepiandrosterone sulfate with cardiovascular disease risk factors in women: longitudinal results from the Massachusetts Women's Health Study. J Clin Epidemiol 52:95-103, 1999.
131. Aarlt W, Haas J, Callies F, et al: Biotransformation of oral dehydroepiandrosterone in elderly men: significant increase in circulating estrogens. J Clin Endocrinol Metab 84:2170-2176, 1999.
132. Morales P, Katz DF, Overstreet JW, et al: The relationship between the motility and morphology of spermatozoa in human semen. J Androl 9:241, 1988.
133. Casson PR, Santoro N, Elkind-Hirsch KE, et al: Postmenopausal dehydroepiandrosterone (DHEA) administration increases insulin-like growth factor-I (IGF-I) and decreases high density lipoprotein (HDL): a six month trial. Fertil Steril 70:107-110, 1998.